Clementia Pharm (CMTA) Now Covered by Leerink Swann
Leerink Swann assumed coverage on shares of Clementia Pharm (NASDAQ:CMTA) in a research report released on Monday, MarketBeat.com reports. The firm issued an outperform rating and a $23.00 price target on the stock. Leerink Swann also issued estimates for Clementia Pharm’s Q3 2017 earnings at ($0.32) EPS, Q4 2017 earnings at ($0.26) EPS, FY2017 earnings at ($4.57) EPS, FY2018 earnings at ($1.17) EPS, FY2019 earnings at ($1.20) EPS, FY2020 earnings at ($1.47) EPS and FY2021 earnings at ($0.40) EPS.
A number of other analysts have also issued reports on the company. Wedbush initiated coverage on Clementia Pharm in a research report on Monday. They issued an outperform rating and a $26.00 target price on the stock. Morgan Stanley initiated coverage on Clementia Pharm in a research report on Monday. They issued an overweight rating and a $27.00 target price on the stock.
Clementia Pharm (NASDAQ:CMTA) opened at 16.33 on Monday. The firm’s 50-day moving average price is $16.04 and its 200 day moving average price is $15.21. Clementia Pharm has a 12-month low of $15.05 and a 12-month high of $18.95. The stock’s market capitalization is $498.51 million.
About Clementia Pharm
Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.
Receive News & Stock Ratings for Clementia Pharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharm and related stocks with our FREE daily email newsletter.